메뉴 건너뛰기




Volumn 34, Issue 1, 2015, Pages 37-43

Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: A randomized, double-blind, placebo-controlled study

Author keywords

administration; overactive bladder; oxybutynin; topical; urinary incontinence, stress; urinary incontinence, urge

Indexed keywords

OXYBUTYNIN; PLACEBO; PROPYLENE GLYCOL; GEL; MANDELIC ACID DERIVATIVE; URINARY TRACT AGENT;

EID: 84916893870     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22504     Document Type: Article
Times cited : (26)

References (14)
  • 1
    • 0141566431 scopus 로고    scopus 로고
    • Prevalence and burden of overactive bladder in the United States
    • Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36.
    • (2003) World J Urol , vol.20 , pp. 327-336
    • Stewart, W.F.1    Van Rooyen, J.B.2    Cundiff, G.W.3
  • 2
    • 34948911446 scopus 로고    scopus 로고
    • Overactive bladder: Treatment options in primary care medicine
    • Sussman DO,. Overactive bladder: Treatment options in primary care medicine. J Am Osteopath Assoc 2007; 107: 379-85.
    • (2007) J Am Osteopath Assoc , vol.107 , pp. 379-385
    • Sussman, D.O.1
  • 3
    • 76049096996 scopus 로고    scopus 로고
    • An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction
    • Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20.
    • (2010) Neurourol Urodyn , vol.29 , pp. 4-20
    • Haylen, B.T.1    De Ridder, D.2    Freeman, R.M.3
  • 4
    • 79955580818 scopus 로고    scopus 로고
    • National community prevalence of overactive balder in the United States stratified by sex and age
    • Coyne KS, Sexton CS, Vats V, et al. National community prevalence of overactive balder in the United States stratified by sex and age. Urology 2011; 77: 1081-7.
    • (2011) Urology , vol.77 , pp. 1081-1087
    • Coyne, K.S.1    Sexton, C.S.2    Vats, V.3
  • 5
    • 0034740818 scopus 로고    scopus 로고
    • Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride
    • Sathyan G, Chancellor MB, Gupta SK,. Effect of OROS® controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001; 52: 409-17.
    • (2001) Br J Clin Pharmacol , vol.52 , pp. 409-417
    • Sathyan, G.1    Chancellor, M.B.2    Gupta, S.K.3
  • 6
    • 0038243258 scopus 로고    scopus 로고
    • Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects
    • Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003; 78: 696-702.
    • (2003) Mayo Clin Proc , vol.78 , pp. 696-702
    • Appell, R.A.1    Chancellor, M.B.2    Zobrist, R.H.3
  • 7
    • 0034967973 scopus 로고    scopus 로고
    • A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence
    • Sanders SW for the Transdermal Oxybutynin Study Group
    • Davila GW, Daugherty CA, Sanders SW for the Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001; 166: 140-5.
    • (2001) J Urol , vol.166 , pp. 140-145
    • Davila, G.W.1    Daugherty, C.A.2
  • 10
    • 84916897205 scopus 로고    scopus 로고
    • Watson Pharma, Inc. Parsippany, NJ: Watson Pharma, Inc.; Revised December 2011
    • Watson Pharma, Inc. GELNIQUE 3% (oxybutynin) gel 3%. Prescribing information. Parsippany, NJ: Watson Pharma, Inc.; Revised December 2011.
    • GELNIQUE 3% (Oxybutynin) Gel 3%. Prescribing Information
  • 11
    • 84870382862 scopus 로고    scopus 로고
    • Dose formulation, dose selection, and phase III results for a flexible dose gel for transdermal oxybutynin delivery
    • Staskin D, Dave K,. Dose formulation, dose selection, and phase III results for a flexible dose gel for transdermal oxybutynin delivery. Neurourol Urodyn 2011; 30: 1028-30.
    • (2011) Neurourol Urodyn , vol.30 , pp. 1028-1030
    • Staskin, D.1    Dave, K.2
  • 12
    • 33644844775 scopus 로고    scopus 로고
    • Transdermal oxybutynin in the treatment of adults with overactive bladder: Combined results of two randomized clinical trials
    • Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: Combined results of two randomized clinical trials. World J Urol 2005; 23: 263-70.
    • (2005) World J Urol , vol.23 , pp. 263-270
    • Dmochowski, R.R.1    Nitti, V.2    Staskin, D.3
  • 13
    • 62049083475 scopus 로고    scopus 로고
    • Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: A randomized, double-blind, placebo controlled, multicenter study
    • Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: A randomized, double-blind, placebo controlled, multicenter study. J Urol 2009; 181: 1764-72.
    • (2009) J Urol , vol.181 , pp. 1764-1772
    • Staskin, D.R.1    Dmochowski, R.R.2    Sand, P.K.3
  • 14
    • 0348025526 scopus 로고    scopus 로고
    • 6th ed. London, UK and Washington, DC: Pharmaceutical Press and the American Pharmacists Association
    • Rowe RC, Sheskey PJ, Quinn ME, et al. Handbook of Pharmaceutical Excipients, 6th ed. London, UK and Washington, DC: Pharmaceutical Press and the American Pharmacists Association; 2009. 593.
    • (2009) Handbook of Pharmaceutical Excipients , pp. 593
    • Rowe, R.C.1    Sheskey, P.J.2    Quinn, M.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.